NO | პროდუქტები | CAS არა | ძირითადი ხარისხის მაჩვენებელი | |||
სიწმინდე | მაქსიმ. მინარევა | მთლიანი გამხსნელი ნარჩენები | ტენიანობა | |||
1 | Fmoc-β-ala-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
2 | Fmoc-d-ala-d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
3 | Fmoc-β-ala-d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
4 | Fmoc-arg (pbf) -arg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
5 | FMOC-β-ala-Arg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
6 | Fmoc-d-arg (pbf) -d-arg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
7 | FMOC-β-ala-d-Arg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
8 | Fmoc-homoarg (pbf) -homoarg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
9 | FMOC-β-Ala-Homoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
10 | Fmoc-asn (trt) -asn (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
11 | FMOC-β-ala-asn (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
12 | Fmoc-asp (otbu) -asp (otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
13 | Fmoc-β-ala-asp (Otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
14 | FMOC-Cys (TRT) -cys (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
15 | FMOC-β-ala-cys (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
16 | FMOC-Cys (ACM) -cys (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
17 | FMOC-β-ala-cys (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
18 | Fmoc-gln (trt) -gln (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
19 | FMOC-β-ala-gln (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
20 | Fmoc-glu (otbu) -glu (otbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
21 | FMOC-β-ala-glu (OTBU) -OH.H2O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
22 | Fmoc-β-ala-gly-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
23 | Fmoc-his (trt) -his (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
24 | FMOC-β-Ala-HIS (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
25 | Fmoc-ile-ite-ოჰ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
26 | Fmoc-β-ala-ile-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
27 | Fmoc-leu-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
28 | Fmoc-β-ala-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
29 | FMOC-D-LEU-D-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
30 | Fmoc-β-ala-d-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
31 | FMOC-LYS (BOC) -LYS (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
32 | FMOC-β-ala-lys (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
33 | FMOC-LYS (გამოყოფა) -lys (გამოყოფა)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
34 | FMOC-β-ala-lys (გამოყოფა)-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
35 | Fmoc-met-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
36 | Fmoc-β-ala-met-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
37 | Fmoc-orn (boc) -orn (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
38 | FMOC-β-ala-orn (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
39 | FMOC-PHE-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
40 | Fmoc-β-ala-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
41 | FMOC-D-PHE-D-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
42 | Fmoc-β-ala-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
43 | Fmoc-pro-pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
44 | Fmoc-β-ala-pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
45 | Fmoc-ser (tbu) -ser (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
46 | FMOC-β-ala-ser (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
47 | Fmoc-ser (trt) -ser (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
48 | FMOC-β-Ala-SER (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
49 | FMOC-THR (TBU) -THR (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
50 | FMOC-β-ALA-THR (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
51 | FMOC-TRP (BOC) -TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
52 | FMOC-β-Ala-Trp (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
53 | FMOC-D-TRP (BOC) -D-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
54 | FMOC-β-Ala-D-Trp (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
55 | Fmoc-tyr (tbu) -tyr (tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
56 | FMOC-β-ala-tyr (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
57 | FMOC-D-Tyr (ET) -D-Tyr (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
58 | FMOC-β-Ala-D-Tyr (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
59 | Fmoc-tyr (me) -tyr (me) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
60 | Fmoc-β-ala-tyr (me) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
61 | FMOC-Val-Val-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
62 | Fmoc-β-ala-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
63 | FMOC-D-CIT-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
64 | Fmoc-β-ala-d-cit-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
65 | Fmoc-β-ala-dab-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
66 | Fmoc- (3- (2-ნაფტილ) -D-ალა) 2-ოჰ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
67 | FMOC-β-ALA-3- (2-ნაფტილ) -D-ალა-ოჰ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
68 | Fmoc- (3- (3- პირიდინილ) -D-ალა) 2-ოჰ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
69 | FMOC-β-ALA-3- (3-პირიდინილ) -D-ალა-ოჰ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
70 | FMOC- (4-ქლორო- D-Phe) 2-ოჰ | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
71 | FMOC-β-ALA-4-Chloro-D-Phe-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
72 | FMOC- (D-4APH (TBUCBM)) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
73 | FMOC-β-ALA-D-4APH (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
74 | Fmoc-aph (l-hor) -aph (l-hor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
75 | FMOC-β-ala-aph (L-Hor) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
76 | FMOC-Lys (IPR, BOC) -Lys (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
77 | FMOC-β-Ala-Lys (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
78 | Fmoc-β-ala-aeea-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
79 | FMOC-AIB-AIB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
80 | Fmoc-β-ala-aib-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
81 | Fmoc-arg-oh | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
82 | H-arg (pbf) -oh | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
83 | Fmoc-d-arg-oh | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
84 | Hd-arg (pbf) -oh | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
86 | H-homoarg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
87 | Fmoc-d-homoarg-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
88 | Hd-homoarg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
89 | Fmoc-asn-oh | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
90 | H-asn (trt) -oh | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
91 | Fmoc-asp-oh | 119062-05-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
92 | H-asp (Otbu) -oh | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
93 | Fmoc-cys-oh | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
94 | H-cys (trt) -oh | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
95 | H-cys (acm) -oh.hcl | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
96 | Fmoc-gln-ოჰ | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
97 | H-gln (trt) -oh | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
98 | FMOC-GLU-OH | 121343-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
99 | H-glu (Otbu) -oh.h2o | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
100 | Fmoc-his-oh | 116611-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
101 | H-–-(trt) -oh | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
102 | Boc-his-oh | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
103 | Fmoc-lys-oh | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
104 | H-lys (BOC) -OH | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
105 | H-lys (გამოყოფა) -OH | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
106 | Fmoc-orn-oh.hcl | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
107 | H-orn (boc) -oh | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
108 | FMOC-SER-OH | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
109 | H-ser (tbu) -oh | 18822-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
110 | H-ser (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
112 | H-Thr (TBU) -OH | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
113 | FMOC-TRP-OH | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
114 | H-trp (boc) -oh | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
115 | FMOC-D-TRP-OH | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
117 | Fmoc-tyr-oh | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
118 | H-tyr (tbu) -oh | 18822-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
119 | FMOC-D-Tyr-OH | 112883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
120 | HD-Tyr (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
121 | H-tyr (me) -oh.hcl | 67423-44-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
122 | FMOC-D-4APH (CBM) -OH | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
123 | HD-4APH (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
124 | Fmoc-lys (ipr) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
125 | H-lys (ipr, boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
კომპენსაცია
Gentolex უზრუნველყოფს შესანიშნავი ხარისხის პროდუქტებს, თუ ნებისმიერი პროდუქტის ხარისხი იზრდება კლიენტის მიერ საჭირო ვადებში, საკმარისი მტკიცებულებებით, ჩვენ მოგაწვდით აუცილებელ ანალიზს და შეფასებას კომპენსაციების პროცედურების შესაქმნელად.
წარმოება
ფარმაცევტული პროდუქტების შესაძლებლობებმა მიაღწია ტონას კლასს, ქიმიური პროდუქტების შესაძლებლობები 100 ტონს+ კლასს აღწევს, შესაძლებლობები კარგად არის აღჭურვილი, რომ მთელ მსოფლიოში კლიენტებს ემსახურებიან.
კვლევა და განვითარება
ყოველწლიურად, R&D გუნდის მიერ არის შექმნილი გეგმა, რომ შეიმუშაოს სხვადასხვა ახალი პროდუქტი, როდესაც მიზნები დადგენილია, გუნდში ყველა წევრს მოუწევს გააგრძელოს KPI პასუხისმგებლობა და სტიმულირების პოლიტიკა.